Neomycin Improves Constipation-Predominant Irritable Bowel Syndrome in a Fashion That Is Dependent on the Presence of Methane Gas: Subanalysis of a Double-Blind Randomized Controlled Study
- 373 Downloads
Recent studies have shown that normalization of the lactulose breath test (LBT) with neomycin leads to a significant reduction in irritable bowel syndrome (IBS) symptoms. This subanalysis was done on the constipation-predominant IBS subgroup of patients (C-IBS) to test the ability of neomycin to improve constipation and its correlation with the elimination of methane on breath test. IBS subjects underwent LBT in a blinded fashion. They were then randomly allocated to neomycin or placebo groups. For the purpose of this analysis, only the C-IBS subjects were identified. They were then evaluated for global improvement, abdominal pain, and constipation severity. The ability of neomycin to eliminate methane and its associated improvement in constipation was also determined. One hundred eleven subjects meeting Rome I criteria for IBS were included in the study. Thirty-nine of these had C-IBS. Of these, 20 received placebo and 19 received neomycin. With neomycin, a global improvement of 36.7±7.9% was seen, compared to 5.0±3.2% for placebo (P < .001) in the intention-to-treat analysis. Constipation was improved by 32.6±9.9% with neomycin compared to 18.7±7.2% for placebo (P=.26). Of the original 111 subjects, 12 demonstrated methane on breath test. All 12 of these patients were constipation predominant. In the methane producers receiving neomycin or placebo, improvement in constipation was significantly greater in those receiving neomycin (44.0±12.3%) compared to placebo (5.0±5.1%) (P < .05). Treatment with neomycin improves constipation in C-IBS. This improvement depends on the presence and elimination of methane on breath test.
KeywordsIrritable bowel syndrome Constipation Methane gas
The authors would like to thank the Beatrice and Samuel A. Seaver Foundation for their support in this ongoing work. We would also like to thank Robert Wade for his expertise in conducting the breath testing for the study. Supported in part by the Beatrice and Samuel A. Seaver Foundation.
- 2.Camilleri M, Chey WY, Mayer EA, Northcutt AR, Heath A, Dukes GE, McSorley D, Mangel AM (2001) A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 161:1733–1740.PubMedCrossRefGoogle Scholar
- 5.Neal KR, Hebden J, Spiller R (1997) Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. Br Med J 314:779–782.Google Scholar
- 13.Lin HC, Pimentel M, Chen JH (2002) Intestinal transit is slowed by luminal methane. Neurogastroenterol Motil 4:437.Google Scholar
- 14.Drossman DA, Richter JE, Talley NJ, et al (eds) (1994) Functional gastrointestinal disorders: Diagnosis, pathophysiology and treatment: A multinational consensus. Little, Brown, Boston.Google Scholar
- 17.Li E (1995) Bacterial overgrowth. In: Yamada T, Alpers DH, Owyang C, Powell DW, Silverstein FE (eds) Textbook of gastroenterology. Lippincott, Philadelphia.Google Scholar
- 19.Pimentel M, Lee H-R, Zaidel O, van der Burg B, Park S, Conklin JL (2004) Methane gas induces prolonged duration and high amplitude contractile activity in the guinea pig ileum. Gastroenterol 126:A165.Google Scholar